A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Dec 2024.
- 05 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 22 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.